N-palmitoylethanolamide synergizes the antinociception of morphine and gabapentin in the formalin test in mice. 2023

Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México, México.

OBJECTIVE The antinociceptive pharmacological interaction between N-palmitoylethanolamide (PEA) and morphine (MOR), as well as gabapentin (GBP), was investigated to obtain synergistic antinociception at doses where side effects were minimal. In addition, the possible antinociceptive mechanism of PEA + MOR or PEA + GBP combinations was explored. METHODS Individual dose-response curves (DRCs) of PEA, MOR and GBP were evaluated in female mice in which intraplantar nociception was induced with 2% formalin. Isobolographic method was used to detect the pharmacological interaction in the combination of PEA + MOR or PEA + GBP. RESULTS The ED50 was calculated from the DRC; the order of potency was MOR > PEA > GBP. The isobolographic analysis was obtained at a 1:1 ratio to determine the pharmacological interaction. The experimental values of flinching (PEA + MOR, Zexp = 2.72 ± 0.2 μg/paw and PEA + GBP Zexp = 2.77 ± 0.19 μg/paw) were significantly lower than those calculated theoretically (PEA + MOR Zadd = 7.78 ± 1.07 and PEA + GBP Zadd = 24.05 ± 1.91 μg/paw), resulting in synergistic antinociception. Pretreatment with GW6471 and naloxone demonstrated that peroxisome proliferator-activated receptor alpha (PPARα) and opioid receptors are involved in both interactions. CONCLUSIONS These results suggest that MOR and GBP synergistically enhance PEA-induced antinociception through PPARα and opioid receptor mechanisms. Furthermore, the results suggest that combinations containing PEA with MOR or GBP could be of interest in aiding the treatment of inflammatory pain.

UI MeSH Term Description Entries
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D010147 Pain Measurement Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies. Analgesia Tests,Analogue Pain Scale,Formalin Test,McGill Pain Questionnaire,Nociception Tests,Pain Assessment,Pain Intensity,Pain Severity,Tourniquet Pain Test,Visual Analogue Pain Scale,Analog Pain Scale,Assessment, Pain,McGill Pain Scale,Visual Analog Pain Scale,Analgesia Test,Analog Pain Scales,Analogue Pain Scales,Formalin Tests,Intensity, Pain,Measurement, Pain,Nociception Test,Pain Assessments,Pain Intensities,Pain Measurements,Pain Questionnaire, McGill,Pain Scale, Analog,Pain Scale, Analogue,Pain Scale, McGill,Pain Severities,Pain Test, Tourniquet,Questionnaire, McGill Pain,Scale, Analog Pain,Scale, Analogue Pain,Scale, McGill Pain,Severity, Pain,Test, Analgesia,Test, Formalin,Test, Nociception,Test, Tourniquet Pain,Tests, Nociception,Tourniquet Pain Tests
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D000077206 Gabapentin A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. 1-(Aminomethyl)cyclohexaneacetic Acid,Apo-Gabapentin,Convalis,Gabapentin Hexal,Gabapentin Stada,Gabapentin-Ratiopharm,Neurontin,Novo-Gabapentin,PMS-Gabapentin,Apo Gabapentin,ApoGabapentin,Gabapentin Ratiopharm,Novo Gabapentin,NovoGabapentin
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D047493 PPAR alpha A nuclear transcription factor. Heterodimerization with RETINOID X RECEPTOR GAMMA is important to metabolism of LIPIDS. It is the target of FIBRATES to control HYPERLIPIDEMIAS. PPARalpha,Peroxisome Proliferator-Activated Receptor alpha,Peroxisome Proliferator Activated Receptor alpha

Related Publications

Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
July 2000, European journal of pharmacology,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
April 1998, General pharmacology,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
April 2015, Pharmacological reports : PR,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
January 2002, Regional anesthesia and pain medicine,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
September 2000, Pharmacological research,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
December 2008, Journal of Korean medical science,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
September 2000, Pharmacology & toxicology,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
March 2010, Phytotherapy research : PTR,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
May 1990, Pharmacology & toxicology,
Myrna Déciga-Campos, and Osmar Antonio Jaramillo-Morales, and Josué Vidal Espinosa-Juárez, and María Elena Aguilera-Martínez, and Rosa Ventura-Martínez, and Francisco Javier López-Muñoz
December 2005, Behavioural pharmacology,
Copied contents to your clipboard!